Results 11 to 20 of about 36,038 (221)

Moxifloxacin-induced neutropenia in 26-year-old man [PDF]

Journal of Infection in Developing Countries, 2018
Moxifloxacin is a fourth generation widely used fluoroquinolone antibiotic. There are three cases of moxifloxacin-induced neutropenia reported in the literature and we report the fourth case.
Tuğba Kula Atik, Emre Ispir, Aykut Aytekin, Ufuk Turhan, Esma Yeniiz, Dilaver Tas, Orhan Bedir   +6 more
doaj   +2 more sources

Cohort Study of Intracameral Moxifloxacin in Postoperative Endophthalmitis Prophylaxis

Ophthalmology and Eye Diseases, 2014
We conducted a cohort study to evaluate post-cataract surgery endophthalmitis rates in relation to prophylactic intracameral moxifloxacin administration.
Virgilio Galvis, Alejandro Tello, Mary Alejandra Sánchez, Paul Anthony Camacho   +3 more
doaj   +2 more sources

Decreased protein binding of moxifloxacin in patients with sepsis? [PDF]

GMS Infectious Diseases, 2017
The mean (SD) unbound fraction of moxifloxacin in plasma from patients with severe sepsis or septic shock was determined by ultrafiltration to 85.5±3.0% (range 81.9 and 91.6%) indicating a decreased protein binding of moxifloxacin in this population ...
Dorn, Christoph, Nowak, Hartmuth, Weidemann, Caroline, Martini, Stefan, Zeitlinger, Markus, Adamzik, Michael, Kees, Frieder   +6 more
doaj   +3 more sources

HERG Protein Plays a Role in Moxifloxacin-Induced Hypoglycemia [PDF]

Journal of Diabetes Research, 2016
The purpose of this study was to investigate the effect of moxifloxacin on HERG channel protein and glucose metabolism. HERG expression was investigated using immunohistochemistry.
Hai-Yan Qiu, Sha-Sha Yuan, Fang-Yuan Yang, Ting-Ting Shi, Jin-Kui Yang   +4 more
doaj   +2 more sources

Periodontal microbiology and microbial etiology of periodontal diseases: Historical concepts and contemporary perspectives

Periodontology 2000, EarlyView., 2023
Abstract This narrative review summarizes the collective knowledge on periodontal microbiology, through a historical timeline that highlights the European contribution in the global field. The etiological concepts on periodontal disease culminate to the ecological plaque hypothesis and its dysbiosis‐centered interpretation.
Georgios N. Belibasakis, Daniel Belstrøm, Sigrun Eick, Ulvi K. Gursoy, Anders Johansson, Eija Könönen   +5 more
wiley   +1 more source

Europe's contribution to the evaluation of the use of systemic antimicrobials in the treatment of periodontitis

Periodontology 2000, EarlyView., 2023
Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera, Arie Jan van Winkelhoff, Paula Matesanz, Katalina Lauwens, Wim Teughels   +4 more
wiley   +1 more source

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis [PDF]

, 2015
Supported by the Global Alliance for TB Drug Development with support from the Bill and Melinda Gates Foundation, the European and Developing Countries Clinical Trials Partnership, U.S. Agency for International Development, U.K.
for the REMoxTB Consortium, McHugh, Timothy D., Crook, Angela M., Gillespie, Stephen H., Phillips, Patrick P.J., Nunn, Andrew J., Pappas, Frances, Murray, Stephen R., Meredith, Sarah K., Mendel, Carl M.   +9 more
core   +1 more source

Supra and subgingival application of antiseptics or antibiotics during periodontal therapy

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases (gingivitis and periodontitis) are characterized by inflammatory processes which arise as a result of disruption of the balance in the oral ecosystem. According to the current S3 level clinical practice guidelines, therapy of patients with periodontitis involves a stepwise approach that includes the control of the patient ...
Elena Figuero, Jorge Serrano, Nicole Birgit Arweiler, Thorsten Mathias Auschill, Ali Gürkan, Gülnur Emingil   +5 more
wiley   +1 more source

Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial [PDF]

, 2010
Background Acute exacerbations contribute to the morbidity and mortality associated with chronic obstructive pulmonary disease (COPD). This proof-of-concept study evaluates whether intermittent pulsed moxifloxacin treatment could reduce the frequency of ...
Jones, PW, Badenhorst J., Sethi S., Cukier A., Miravitlles, M, Sethi, S, Clancy L., Marlize Schmitt Theron, Bitter-Suermann S., Miravitlles Marc, Bettendorf A., Nadar R., Sanjay Sethi, Queguiner A., Rubinstein, E, Potena A., Naude G., PULSE Study group, Abenhaim N., Schroder-Babo W., Di Bartolo C., null null, Theron, MS, Kroemer B., Ferreyra R., del Campo F., de Oliveira J. A., Wedzicha J. A., Jones P. W., Killian J., Watz H., Millar A., Toubis M., Jadwiga A Wedzicha, Molitor S., Anzueto A., Gebhardt R., Groth G., Sanchez R. P., Peraza R. B., Sharafkhaneh A., Bassaris H., Smith C., Wilson Robert, Merida F. C., Fritscher C., Joubert J., Sethi Sanjay, Llamas F. S., Parada M., Alvarez-Sala L., Rubinstein Ethan, Raz P., Cote C., Vlastos F., Legnani D., Richter K., Menendez R., Barnes N. C., Viljoen J., Hasan S., Lalanne G., Wilson, R, Rubinstein E., Rastogi P., Elliott M., Bolio F. T., Fernandez P., Gaines S., Colberg K., Schaberg T., Harari S., Triot P., Monso E., Nieuwoudt G., Westerhausen U., Paul W Jones, Mans W., O'Connell F., Prins M., Dichmann R., Miravitlles M., Taminau D., Raz M., Ignacio J. M., Plautz M., Jones Paul W, Theron M. S., Zeltser D., Habib M., Kawley F., Jardim J. B., Linnhoff A., Weiler Z., Cutillas J. R., Wedzicha Jadwiga A, Robert Wilson, Barros M., Stockley R., Ethan Rubinstein, Wedzicha, JA, Wilson R., Mahutte C. K., Bugnas B., Littner M., Marc Miravitlles, Luna C., Theron Marlize, Hosp H. A., Pozzi E., Groth J., Rubinstein, Ethan, Wilson, Robert, Theron, Marlize S, Jones, Paul W, Sethi, Sanjay, Miravitlles, Marc, the PULSE Study group, Wedzicha, Jadwiga A   +118 more
core   +1 more source

Fluoroquinolones’ Biological Activities against Laboratory Microbes and Cancer Cell Lines

Molecules, 2022
Development of novel derivatives to rein in and fight bacteria have never been more demanding, as microbial resistance strains are alarmingly increasing.
Ghadeer A. R. Y. Suaifan, Aya A. M. Mohammed, Bayan A. Alkhawaja   +2 more
doaj   +1 more source